Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Exploring the companies and themes that make up this emerging and exciting new sector
Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104
Field Trip will focus on Treatment-Resistant Depression and Postpartum Depression as indications for drug development of FT-104.
Wesana Health Announces Closing of PsyTech Acquisition
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1
Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
The Economics of Psychedelics
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering with Leading Canadian Fresh and Dried Mushroom Producers on East Coast Facility
Red Light Holland closes on its majority ownership in Acadian Exotic Mushrooms, now holding a 51% interest.
Oregon Psilocybin Panel Teams Up With Harvard To Research Psychedelic History And Impacts Of Reform
An Oregon state panel charged with advising on the implementation of a legal psilocybin therapy program has cleared a team of researchers to produce a comprehensive report on the science, history and culture of the psychedelic as regulators prepare to license facilities to administer it.
Washington Officials Join Cancer Patients In Federal Court Argument Pushing DEA To Allow Psilocybin Access
The Washington State attorney general’s office appeared alongside lawyers representing cancer patients on Thursday, telling a federal appeals panel that people in end-of-life care deserve legal access to psilocybin under state and federal right-to-try laws.
The DEA Proves It Must Be Immediately Abolished
The DEA fights to keep psychedelic drugs illegal while it admits these drugs have valuable medical uses. Meanwhile, Americans are dying every day from lack of legal access.